Conflict of interest

Y.O. received honoraria from Daiichi-Sankyo, Pfizer, Chugai, Lilly and Kyowa Kirin. T.Y. received honoraria from Kyowa-Kirin, Pfizer, Chugai, Eli Lilly, MSD, AstraZeneca and Eisai. K.T. received honoraria from Ono, Chugai, Taiho and Novartis. E.I. received honoraria from Eli Lilly, and research funding from MSD, Ono, Janssen Pharma and Takeda. Y.M. received honoraria from Ono, MSD, Takeda, Eisai and Bristol Myers Squibb, and research funding from MSD and Ono. S.Y. received research funding from Otsuka. D.M. received honoraria from Janssen, Nippon Shinyaku, Eisai, Mundipharma, Kyowa Kirin, Chugai, Zenyaku, MSD, SymBio, Sanofi, AbbVie, Takeda, Astra Zeneca and Bristol Myers Squibb, and research funding from Biopharma, Novartis, Kyowa Kirin, Ono, Chugai, Janssen, Takeda, Otsuka, Sanofi, Astellas, Bristol Myers Squibb, AbbVie, Eisai, MSD, Taiho and Astra Zeneca. T.M. received honoraria from Astra Zeneca, Chugai and Myriadgenetics. E.B. received honoraria from Chugai, and Daiichi-Sankyo, and research funding from Taiho and Chugai. T.KU. received honoraria from Chugai. T.KI. received honoraria from Sanofi. S.N. received honoraria from Kyowa Kirin. A.S. received honoraria and scholarship donation from Chugai and Taiho. T.T. received honoraria from Daiichi-Sankyo, Chugai and Eli Lilly. Other authors declare that there are no conflicts of interest associated with this manuscript. The other authors have no conflict of interest.

Ethics approval

Not applicable.

Informed consent

Formal consent was not required for this type of study.

Consent to participate

Not applicable.

Consent for publication

All authors consented to the publication of this study.